$1.78 Million in Sales Expected for Achaogen Inc (AKAO) This Quarter
Equities research analysts expect that Achaogen Inc (NASDAQ:AKAO) will report $1.78 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Achaogen’s earnings. The lowest sales estimate is $800,000.00 and the highest is $4.80 million. Achaogen posted sales of $10.73 million during the same quarter last year, which suggests a negative year over year growth rate of 83.4%. The company is expected to announce its next earnings report on Tuesday, March 13th.
According to Zacks, analysts expect that Achaogen will report full year sales of $1.78 million for the current fiscal year, with estimates ranging from $9.30 million to $14.20 million. For the next year, analysts forecast that the company will post sales of $14.65 million per share, with estimates ranging from $5.60 million to $25.00 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Achaogen.
AKAO has been the topic of a number of recent research reports. Mizuho reiterated a “buy” rating and issued a $28.00 price objective on shares of Achaogen in a report on Monday, October 30th. SunTrust Banks lowered their price objective on shares of Achaogen to $27.00 and set a “buy” rating on the stock in a report on Wednesday, January 3rd. Zacks Investment Research downgraded shares of Achaogen from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. HC Wainwright boosted their target price on shares of Achaogen from $25.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, Stifel Nicolaus lowered their target price on shares of Achaogen from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, November 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Achaogen has a consensus rating of “Buy” and a consensus price target of $26.16.
A number of hedge funds have recently added to or reduced their stakes in AKAO. Legal & General Group Plc bought a new position in Achaogen during the second quarter worth $168,000. Clear Harbor Asset Management LLC bought a new position in Achaogen during the fourth quarter worth $177,000. Tower Research Capital LLC TRC boosted its position in Achaogen by 375.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock worth $201,000 after purchasing an additional 14,725 shares during the period. Ardsley Advisory Partners bought a new position in Achaogen during the second quarter worth $217,000. Finally, JPMorgan Chase & Co. boosted its position in Achaogen by 691.2% during the second quarter. JPMorgan Chase & Co. now owns 11,077 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 9,677 shares during the period. 86.56% of the stock is owned by hedge funds and other institutional investors.
Achaogen (NASDAQ AKAO) traded up $0.31 during midday trading on Friday, hitting $10.85. 656,601 shares of the stock were exchanged, compared to its average volume of 1,420,000. The company has a quick ratio of 6.99, a current ratio of 6.99 and a debt-to-equity ratio of 0.08. Achaogen has a 12 month low of $9.83 and a 12 month high of $27.79. The firm has a market capitalization of $459.97, a P/E ratio of -3.23 and a beta of 1.27.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.